Why have studies of tailored anti-platelet therapy failed so far?
Summary Published data linking clopidogrel non-responsiveness to adverse ischaemic events lead to the suggestion that the magnitude of platelet inhibition by clopidogrel can be monitored and individually adjusted. This has been tested in randomised clinical trials (ARCTIC, GRAVITAS and TRIGGER-PCI),...
Published in: | Thrombosis and Haemostasis |
---|---|
Main Authors: | , |
Format: | Article in Journal/Newspaper |
Language: | English |
Published: |
Georg Thieme Verlag KG
2013
|
Subjects: | |
Online Access: | http://dx.doi.org/10.1160/th13-03-0250 http://www.thieme-connect.de/products/ejournals/pdf/10.1160/TH13-03-0250.pdf |
id |
crthieme:10.1160/th13-03-0250 |
---|---|
record_format |
openpolar |
spelling |
crthieme:10.1160/th13-03-0250 2024-05-19T07:35:45+00:00 Why have studies of tailored anti-platelet therapy failed so far? Siller-Matula, Jolanta M. Jilma, Bernd 2013 http://dx.doi.org/10.1160/th13-03-0250 http://www.thieme-connect.de/products/ejournals/pdf/10.1160/TH13-03-0250.pdf en eng Georg Thieme Verlag KG Thrombosis and Haemostasis volume 110, issue 10, page 628-631 ISSN 0340-6245 2567-689X journal-article 2013 crthieme https://doi.org/10.1160/th13-03-0250 2024-05-01T07:17:55Z Summary Published data linking clopidogrel non-responsiveness to adverse ischaemic events lead to the suggestion that the magnitude of platelet inhibition by clopidogrel can be monitored and individually adjusted. This has been tested in randomised clinical trials (ARCTIC, GRAVITAS and TRIGGER-PCI), but despite reducing platelet reactivity, a strategy of therapy adjustment based on platelet function monitoring did not reduce the incidence of cardiac ischaemic events. Several critical issues regarding the design of these trials, which might in part have led to negative results, are discussed in this article. Article in Journal/Newspaper Arctic Thieme Thrombosis and Haemostasis 110 10 628 631 |
institution |
Open Polar |
collection |
Thieme |
op_collection_id |
crthieme |
language |
English |
description |
Summary Published data linking clopidogrel non-responsiveness to adverse ischaemic events lead to the suggestion that the magnitude of platelet inhibition by clopidogrel can be monitored and individually adjusted. This has been tested in randomised clinical trials (ARCTIC, GRAVITAS and TRIGGER-PCI), but despite reducing platelet reactivity, a strategy of therapy adjustment based on platelet function monitoring did not reduce the incidence of cardiac ischaemic events. Several critical issues regarding the design of these trials, which might in part have led to negative results, are discussed in this article. |
format |
Article in Journal/Newspaper |
author |
Siller-Matula, Jolanta M. Jilma, Bernd |
spellingShingle |
Siller-Matula, Jolanta M. Jilma, Bernd Why have studies of tailored anti-platelet therapy failed so far? |
author_facet |
Siller-Matula, Jolanta M. Jilma, Bernd |
author_sort |
Siller-Matula, Jolanta M. |
title |
Why have studies of tailored anti-platelet therapy failed so far? |
title_short |
Why have studies of tailored anti-platelet therapy failed so far? |
title_full |
Why have studies of tailored anti-platelet therapy failed so far? |
title_fullStr |
Why have studies of tailored anti-platelet therapy failed so far? |
title_full_unstemmed |
Why have studies of tailored anti-platelet therapy failed so far? |
title_sort |
why have studies of tailored anti-platelet therapy failed so far? |
publisher |
Georg Thieme Verlag KG |
publishDate |
2013 |
url |
http://dx.doi.org/10.1160/th13-03-0250 http://www.thieme-connect.de/products/ejournals/pdf/10.1160/TH13-03-0250.pdf |
genre |
Arctic |
genre_facet |
Arctic |
op_source |
Thrombosis and Haemostasis volume 110, issue 10, page 628-631 ISSN 0340-6245 2567-689X |
op_doi |
https://doi.org/10.1160/th13-03-0250 |
container_title |
Thrombosis and Haemostasis |
container_volume |
110 |
container_issue |
10 |
container_start_page |
628 |
op_container_end_page |
631 |
_version_ |
1799474770759122944 |